Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents

University of North Carolina (UNC)

Status and phase

Completed

Phase 2

Conditions

Single Episode Major Depression Without Psychotic Symptoms

Schizophreniform Disorder

Mood Disorder NOS

Severe Major Depression With Psychotic Features

Schizoaffective Disorder

Autistic Disorder

Bipolar II Disorder

Bipolar I Disorder

Schizophrenia

Child Development Disorders, Pervasive

Severe Mood Disorder With Psychotic Features

Psychosis NOS

Asperger Syndrome

Treatments

Drug: Latuda©

Study type

Interventional

Funder types

Other

Identifiers

NCT01731119

12-2302

Details and patient eligibility

About

The overarching purpose of this pilot study is to collect preliminary data regarding the variability of weight gain associated with lurasidone (Latuda©) treatment of antipsychotic naive children and adolescents in order to inform decisions about including a lurasidone arm in a future large scale trial of different approaches to minimize antipsychotic associated weight gain in the pediatric population. In adults, lurasidone appears to cause minimal weight gain. The participants will be 6-19 years old with psychotic spectrum, mood spectrum, or autism spectrum disorders. They will have 4 weeks or less of lifetime antipsychotic exposure.

Full description

This is a multi-site, 12-week, open-label study assessing the weight and metabolic changes associated with lurasidone treatment. Antipsychotic (AP) naive subjects will start open-label treatment by following a flexible titration schedule. Quasi-antipsychotic naive subjects (less than 4 weeks of total AP treatment) will be started on lurasidone and tapered off the other antipsychotic over an estimated 4 weeks depending on the dose and tolerability of the prior antipsychotic. Other psychoactive medications including antidepressants, benzodiazepines, stimulants, alpha-2 agonists, and mood stabilizers are allowed as long as the dose is not changed, unless it is clinically necessary. Assessments of weight, efficacy, and side effects are conducted at baseline, week 2, week 4, week 8, and week 12. The primary outcome is percent change in weight. The secondary outcomes include psychiatric efficacy measures and side effects.

Enrollment

9 patients

Sex

All

Ages

6 to 19 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Male and female children and adolescents between 6 and 19 years of age of any race or ethnicity
Subject must meet Diagnostic Statistical Manual (DSM)-IV-Text Revision (TR) criteria for a psychotic spectrum, mood spectrum or autism spectrum disorder as defined by one of the following diagnoses:
- schizophrenia (any type)
- schizoaffective disorder
- schizophreniform disorder
- psychosis Not Otherwise Specified (NOS)
- autistic disorder with significant irritability/aggression (Aberrant Behavioral Checklist-Community (ABC-C) Irritability subscale score of greater than or equal to 18)
- Asperger syndrome with significant irritability/aggression (ABC-C Irritability subscale score of greater than or equal to 18)
- pervasive developmental disorder NOS with significant irritability/aggression (ABC-C Irritability subscale score of greater than or equal to 18)
- bipolar type I
- bipolar type II
- mood disorder NOS
- major depression with psychotic features
- major depression (unresponsive to 2 different antidepressants)
- severe mood dysregulation (SMD) according to Leibenluft and colleagues broad spectrum bipolar disorder
Subjects must have ≤ 4 weeks of lifetime exposure to an antipsychotic medication at any dosage. These medications include olanzapine (Zyprexa©), quetiapine (Seroquel©), risperidone (Risperdal©), ziprasidone (Geodon©), aripiprazole (Abilify©), asenapine (Saphris©), iloperidone (Fanapt©), lurasidone (Latuda©), haloperidol, chlorpromazine, perphenazine, fluphenazine, thiothixene, or clozapine
Subjects on other psychoactive medications are asked not to change dose of those medications during the course of the study unless clinically necessary
Sexually active girls must agree to use two effective forms of birth control (i.e. hormonal or spermicidal and barrier) or be abstinent)
Primary caretaker is able to participate in study appointments as is clinically indicated
Ability of child to participate in all aspects of the protocol per investigator's clinical judgment
After considering all aspects of study participation the subject (if an adult) or subject's parent or Legally Authorized Representative (LAR) must consent to participation
After considering all aspects of study participation, the subject must assent to participation if it is developmentally appropriate to obtain assent

Exclusion criteria

Based on current or lifetime DSM-IV-TR criteria, a diagnosis of Eating Disorder (Anorexia Nervosa or Bulimia Nervosa)
Based on DSM-IV-TR criteria, a diagnosis of Substance Dependence Disorder (other than tobacco dependence) within the past month
Treatment with the following concomitant medications: strong CYP3A4 inhibitors (ex: Ketoconazole), strong CYP3A4 inducers (ex: Rifampin)
Current or past treatment with lurasidone (Latuda©) that resulted in a non-response or intolerance
Females who are pregnant or breast-feeding
Ongoing or previously undisclosed child abuse requiring new department of social service intervention
Subjects who, in the Investigator's opinion, might not be suitable for the study